The University of Chicago Header Logo

Connection

Mark J. Ratain to Randomized Controlled Trials as Topic

Back to Details
This is a "connection" page, showing publications Mark J. Ratain has written about Randomized Controlled Trials as Topic.
Mark J. Ratain
Connection Strength
2.366
Randomized Controlled Trials as Topic
  1. Might cigarettes be a "smoking gun" to reduce taxane myelotoxicity? Clin Cancer Res. 2012 Aug 15; 18(16):4219-21.
    View in: PubMed
    Score: 0.313
  2. Resampling phase III data to assess phase II trial designs and endpoints. Clin Cancer Res. 2012 Apr 15; 18(8):2309-15.
    View in: PubMed
    Score: 0.302
  3. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011 Jul 20; 103(14):1093-100.
    View in: PubMed
    Score: 0.290
  4. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies. Cancer J. 2009 Sep-Oct; 15(5):426-30.
    View in: PubMed
    Score: 0.256
  5. Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer. 2009 Jan; 45(2):275-80.
    View in: PubMed
    Score: 0.243
  6. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst. 2007 Oct 03; 99(19):1455-61.
    View in: PubMed
    Score: 0.224
  7. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative. Clin Cancer Res. 2007 Feb 01; 13(3):781-2.
    View in: PubMed
    Score: 0.214
  8. Meaningful use of pharmacogenetics. Clin Pharmacol Ther. 2014 Dec; 96(6):650-2.
    View in: PubMed
    Score: 0.092
  9. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res. 2012 Jan 15; 18(2):577-84.
    View in: PubMed
    Score: 0.075
  10. Bar the windows but open the door to randomization. J Clin Oncol. 2010 Jul 01; 28(19):3104-6.
    View in: PubMed
    Score: 0.067
  11. Individualizing dosing of irinotecan. Clin Cancer Res. 2010 Jan 15; 16(2):371-2.
    View in: PubMed
    Score: 0.066
  12. Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? J Clin Oncol. 2005 Nov 01; 23(31):8124-5; author reply 8125-6.
    View in: PubMed
    Score: 0.049
  13. EGFR pharmacogenomics: the story continues to mutate and evolve. Am J Pharmacogenomics. 2005; 5(2):137-9.
    View in: PubMed
    Score: 0.046
  14. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022. Ann Oncol. 2023 01; 34(1):48-60.
    View in: PubMed
    Score: 0.040
  15. Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy. Clin Pharmacol Ther. 2020 09; 108(3):625-634.
    View in: PubMed
    Score: 0.034
  16. The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care. Clin Pharmacol Ther. 2019 12; 106(6):1179-1183.
    View in: PubMed
    Score: 0.032
  17. Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clin Cancer Res. 2013 Dec 01; 19(23):6430-7.
    View in: PubMed
    Score: 0.021
  18. Hairy cell leukemia. Current management. Hematol Oncol Clin North Am. 1990 Apr; 4(2):489-502.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.